ArticleFrontiers in oncology2026
Prediction of pulmonary infection during chemotherapy in non-small cell lung cancer: development and internal validation of a nomogram.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and internally validate a nomogram for predicting pulmonary infection during chemotherapy in patients with non-small cell lung cancer (NSCLC). Methods: This retrospective study included 246 NSCLC patients receiving cytotoxic chemotherapy. The primary outcome was pulmonary infection during chemotherapy. Patients were randomly divided into training (n=196) and validation (n=50) cohorts. Predictors were selected using AIC-guided forward stepwise logistic regression to construct a nomogram. Model performance was evaluated by discrimination, calibration, threshold-based classification metrics, and decision curve analysis, with internal validation performed using bootstrap resampling. Results: Pulmonary infection occurred in 55 patients (22.4%). The final model included five predictors: absolute neutrophil count, serum albumin, age, combined immunotherapy, and chronic obstructive pulmonary disease. The apparent AUC was 0.786 (95% CI 0.703-0.869), with an optimism-corrected AUC of 0.735 and a validation AUC of 0.765 (95% CI 0.562-0.968). The nomogram classified patients into low-, intermediate-, and high-risk groups with infection rates of 5.4%, 18.2%, and 37.5%, respectively. Decision curve analysis suggested modest clinical net benefit within clinically relevant threshold probability ranges. Conclusion: This internally validated nomogram, based on routinely available pre-chemotherapy variables, may provide a practical approach for preliminary pulmonary infection risk stratification in patients with NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.